Orion Nutraceuticals, a Cannabis Life Sciences Company, Announces Listing on CSE

Orion Nutraceuticals Inc., (CSE:ORI) (the “Company” or “Orion”) a cannabis life science company, is pleased to announce its listing on the CSE.

Orion Nutraceuticals, in conjunction with its network of sports medicine experts, is creating a line of sports medicine, CBD based, products. Our target market is athletes, athletic therapists, sports medicine retailers, homeopathic and pharmaceutical companies, manufacturers, distributors, wholesalers, consumers and retailers.

In conjunction with its professional sports strategic alliances, the Company is poised to advance research and development in the plant science sector, deliver science-based products and services to the mainstream, with proprietary brands and products.

“We are extremely excited to launch Orion Nutraceuticals as Canada celebrates the legalization of recreational cannabis,” said Jonathan Fiteni, CEO of Orion Nutraceuticals. “We aim to set a new standard in cannabis life science by producing and developing innovative sports medicine products with key, strategic partners in the industry. Through our partners in Colombia, FCM Global, and our domestic cannabis production facility, we intend to become the leaders in cannabis derived CBD therapies.”

Orion is a Vancouver, British Columbia based company that aims to become an ACMPR Licensed Producer through its subsidiary Medic Oasis. Medic Oasis currently has a license under review with Health Canada to become a licensed producer in Quebec. The project expects to receive a Cultivation License from Health Canada in early 2019.

Orion Nutraceuticals is focused on global expansion, beginning with its stake in FCM Global. FCM Global S.A.S. is a fully licensed Colombian medical cannabis company producing a range of extracts, isolates, oils, and micro-emulsions in support of finished goods for manufacturers in legal markets worldwide. Headquartered in Medellin, with a 235,800 sq. ft production facility in La Ceja, the FCM Global platform encompasses genetics, cultivation, extraction, quality testing, formulation, and distribution. FCM Global’s “Co-Sourced Colombia” model reliably delivers lower production costs and high-quality inputs at scale to its clients in the nutritional, wellness, pharmaceutical, and research sectors. FCM Global will soon break ground on FCM Tolima, a planned 450-hectare cultivation and production site which will have production capabilities of over 1,000 tons of cannabis oil at full capacity. For further information please visit www.fcm-global.com.

“FCM congratulates Orion on achieving another significant milestone”, says Carlos Velasquez, CEO of FCM Global. “We are proud to partner with Orion as they execute their winning formula of high-quality products plus large-scale production capacity.”

About Orion Nutraceuticals Inc.
Orion Nutraceuticals Inc. aims to set a new standard in cannabis life science by producing and developing innovative products with key strategic partners in the industry. In conjunction with its professional sports strategic alliances, the company is poised to advance research and development in the plant science sector, deliver science-based products and services, and market CBD therapies to the mainstream with proprietary brands and products. Medic-Oasis, Orion’s subsidiary, has submitted its application for anACMPR license and is currently under review with Health Canada. Build out is expected to begin in Q1 2019, with completion of the 30,000 square foot facility expected by Q3 2019.Orion Nutraceuticals is partners with Colombian based medical cannabis corporation FCM Global. FCM supplies pharmaceutical, nutritional, wellness, and cosmetic companies in legal markets worldwide with customized medical cannabis extracts, oils, and isolates at commercial scale. Orion shares trade in Canada on the CSE under the symbol ORI.

ON BEHALF OF THE BOARD

Jonathan Fiteni, CEO
Orion Nutraceuticals Inc.
www.orionnutra.ca

Investor Relations
Robin Linden, Director
1.604.313.2768
investors@orionnutra.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Source: www.orionnutra.ca